Xilio Therapeutics (XLO) Fundamentals 2026 — Revenue Analysis | SniperIQ
Xilio Therapeutics (XLO) is a US-listed Healthcare company in Biotechnology with a market capitalization of $57M, trading at $8.61 on the NASDAQ. This SniperIQ fundamentals page covers Xilio Therapeutics's valuation, profitability (net margin -58.5%), revenue ($44M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Xilio Therapeutics's market cap?
Xilio Therapeutics (XLO) has a market capitalization of approximately $57M, trading at $8.61 on the NASDAQ. Market cap moves with the live share price.
What is Xilio Therapeutics's P/E ratio?
Xilio Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 19.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Xilio Therapeutics?
Xilio Therapeutics runs a net profit margin of -58.5%, a gross margin of 70.7%, and an operating margin of -79.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Xilio Therapeutics generate?
Xilio Therapeutics reported revenue of $44M for fiscal year 2025, with net income of -